Angina
European Medicines Agency Adopts Positive Opinion for Ranolazine for Treatment of Chronic Angina
Published in Cardiovascular Business Week, May 6th, 2008
Following this positive recommendation from the CHMP, CV Therapeutics expects the European Commission to issue full marketing authorization for ranolazine by the end of June. The brand name for ranolazine in the product labeling is Latixa(TM).
The approved indication states that ranolazine "is indicated as add-on therapy for the symptomatic treatment of patients with stable...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
More Articles from Cardiovascular Business Week
- Anxiety Disorders
How to Recognize the Signs and Symptoms of Anxiety and Depressive Illnesses - Arrhythmia
American Heart Association Launches First of New Journals - Circulation: Arrhythmia and Electrophysiology Premieres - Asthma
Resolvyx Pharmaceuticals Raises $25 Million in Series B Financing - Atrial Fibrillation
Early Study Results Demonstrate Ability of Innovative RF Ablation Catheter to Quickly and Easily Isolate Pulmonary Veins in Atrial Fibrillation Patients - Bioengineering
CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing - Bioengineering
CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership - More from this issue of Cardiovascular Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
